Accounts Receivable, after Allowance for Credit Loss, Current of NRX Pharmaceuticals, Inc. from 31 Dec 2020 to 30 Sep 2025
Taxonomy & unit
us-gaap: USD
Description
Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.
Summary
NRX Pharmaceuticals, Inc. quarterly Accounts Receivable, after Allowance for Credit Loss, Current in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
NRX Pharmaceuticals, Inc. Accounts Receivable, after Allowance for Credit Loss, Current for the quarter ending 30 Sep 2025 was $239,000.
* An asterisk sign (*) next to the value indicates that the value is likely invalid.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.